Freestone Capital Holdings LLC Purchases 630 Shares of DexCom, Inc. (NASDAQ:DXCM)

Freestone Capital Holdings LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 14,235 shares of the medical device company’s stock after buying an additional 630 shares during the quarter. Freestone Capital Holdings LLC’s holdings in DexCom were worth $1,974,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. DSM Capital Partners LLC bought a new stake in shares of DexCom during the fourth quarter valued at approximately $28,000. Crewe Advisors LLC bought a new stake in DexCom in the 1st quarter worth approximately $29,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Riverview Trust Co bought a new stake in DexCom in the 1st quarter worth approximately $32,000. Finally, MV Capital Management Inc. grew its position in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research analyst reports. Morgan Stanley cut their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Oppenheimer cut their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday. Redburn Atlantic assumed coverage on shares of DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price for the company. Finally, Royal Bank of Canada cut their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $112.60.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold a total of 4,112 shares of company stock worth $480,861 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Price Performance

DXCM stock traded down $44.29 during mid-day trading on Friday, hitting $63.56. The company had a trading volume of 40,282,656 shares, compared to its average volume of 3,182,912. The company has a market capitalization of $25.28 billion, a price-to-earnings ratio of 40.41, a P/E/G ratio of 2.74 and a beta of 1.16. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a 50-day moving average price of $116.63 and a 200 day moving average price of $124.29.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.34 EPS. On average, research analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.